https://openbell.ai/ 2026-10-26T17:38:17.612Z hourly 1.0 https://openbell.ai/support 2026-10-26T17:38:17.612Z monthly 0.7 https://openbell.ai/privacy 2026-10-26T17:38:17.612Z monthly 0.5 https://openbell.ai/terms 2026-10-26T17:38:17.612Z monthly 0.5 https://openbell.ai/feed.json 2026-10-26T17:38:17.612Z hourly 0.8 https://openbell.ai/news/RECI:1793035928000 2026-10-26T17:32:08.000Z daily 0.9 https://cdn.brandfetch.io/RECI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Real Estate Credit Investments Ltd. Delays Interim Financial Results and Continues Restructuring Real Estate Credit Investments Ltd. said it could not publish interim results for the six months ended June 30, 2026, by the required deadline. The Board is pursuing restructuring and deleveraging initiatives and engaging with lenders, but these efforts remain subject to material uncertainties and approvals. Given the company’s financial position and the priority of creditor claims, the Board said prospects for recovery by ordinary shareholders are extremely limited. https://openbell.ai/news/AVCT:1793035923000 2026-10-26T17:32:03.000Z daily 0.9 https://cdn.brandfetch.io/AVCT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Avacta Reports Positive Phase 1a/1b Data for Faridoxorubicin in Salivary Gland Cancer Avacta Group reported updated Phase 1a/1b trial data for faridoxorubicin (AVA6000), showing median progression-free survival of 11.4 months in a defined subset of patients with salivary gland cancer, compared with historical benchmarks of 6 to 6.7 months. The company also reported clinically meaningful tumor shrinkage in most patients in the subset. Avacta said the results support the potential of its pre|CISION platform to target drug payloads to tumors while limiting systemic toxicity. https://openbell.ai/news/ASND:1793034120000 2026-10-26T17:02:00.000Z daily 0.9 https://cdn.brandfetch.io/ASND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ascendis Pharma Announces Positive Long-Term Data for TransCon PTH in Hypoparathyroidism Ascendis Pharma reported pooled Phase 2 and Phase 3 data showing TransCon PTH (palopegteriparatide) was associated with statistically significant improvements in kidney function and normalized 24-hour urine calcium in adults with hypoparathyroidism, sustained for up to five years. At the final trial visit, 98% of patients were independent of active vitamin D and 95% were independent of therapeutic calcium doses. The results were presented at Kidney Week 2026; the article did not report financial results or a stock-price reaction. https://openbell.ai/news/ALLEI:1793034116000 2026-10-26T17:01:56.000Z daily 0.9 https://cdn.brandfetch.io/ALLEI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alleima Reports Third Quarter 2026 Financial Results Alleima reported its financial results for the third quarter and first nine months ended September 30, 2026. Adjusted operating profit for the period was below market expectations. The article provides no specific financial figures or stock-price impact. https://openbell.ai/news/COV:1793034102000 2026-10-26T17:01:42.000Z daily 0.9 https://cdn.brandfetch.io/COV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Covivio Reports Nine-Month 2026 Revenue Growth and Confirms Guidance Covivio reported group-share revenue of €531 million for the first nine months of 2026, equivalent to €804 million at 100% ownership of its properties. Revenue grew organically by 2.7% at constant scope, supported by its office, residential and hotel segments. The company confirmed its 2026 financial guidance and reported €1.9 billion in liquidity. https://openbell.ai/news/FRA:1793034099000 2026-10-26T17:01:39.000Z daily 0.9 https://cdn.brandfetch.io/FRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fraport Reports Preliminary Q3 2026 Results Exceeding Analyst Consensus Fraport reported preliminary Q3 2026 EBITDA of approximately €595 million and EBIT of approximately €407 million, beating analyst consensus by nearly 4% and 5%, respectively. The outperformance was primarily driven by a one-off gain of about €24 million from selling its 50% stake in Medical Airport Service GmbH. Fraport confirmed its 2026 financial guidance and plans to publish full third-quarter results on November 4, 2026. https://openbell.ai/news/HTRO:1793032385000 2026-10-26T16:33:05.000Z daily 0.9 https://cdn.brandfetch.io/HTRO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hexatronic Group AB Reports Third Quarter 2026 Results Hexatronic Group AB reported its third-quarter 2026 results, with analysts describing overall performance as strong. The Data Center segment was identified as the leading driver of operational results. The article provides no revenue, profit, growth percentages, or stock-price figures. https://openbell.ai/news/NTG:1793032311000 2026-10-26T16:31:51.000Z daily 0.9 https://cdn.brandfetch.io/NTG/w/400/h/400?c=1idopYfmtR7ZKg8QMud NTG Nordic Transport Group A/S Upgrades Full-Year 2026 Guidance Based on preliminary third-quarter 2026 results, NTG Nordic Transport Group raised its full-year adjusted EBIT guidance to DKK 660–685 million from DKK 625–650 million. It now expects special items of approximately DKK 50 million, compared with its previous estimate of DKK 30–35 million. The revised outlook reflects expected positive volume development in Road & Logistics and Air & Ocean amid a modest, uneven European recovery; it assumes current exchange rates and excludes potential 2026 acquisitions. https://openbell.ai/news/KLAC:1793026914000 2026-10-26T15:01:54.000Z daily 0.9 https://cdn.brandfetch.io/KLAC/w/400/h/400?c=1idopYfmtR7ZKg8QMud KLA Corporation Reports Significant Backlog Growth Driven by AI Infrastructure Demand KLA Corporation reported that its backlog rose to $12.57 billion for the fiscal year ended June 30, 2026, up from $7.86 billion a year earlier. The company attributed the increase to demand for inspection and process control systems amid AI infrastructure and high-performance computing expansion, as chip packaging complexity raises the need for yield-focused inspection. Services contributed approximately 23% of fiscal 2026 revenue. The article did not report total revenue, profit, or stock-price movements. https://openbell.ai/news/DCC:1793023331000 2026-10-26T14:02:11.000Z daily 0.9 https://cdn.brandfetch.io/DCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ongoing Acquisition Process for DCC plc DCC plc remains the target of an acquisition process involving a consortium of Energy Capital Partners and KKR. Regulatory filings dated October 26, 2026, disclose that J.P. Morgan Securities and Goldman Sachs International are acting as connected exempt principal traders and advisers. The filings report share dealings and derivative transactions related to the offer; no financial terms or market impact are stated.